Dermasorb Ta (triamcinolone acetonide/emollient combination no.86)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

USES: This medication is used to treat a variety of skin conditions (such as eczema, dermatitis, allergies, rash). Triamcinolone reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a medium- to strong-potency corticosteroid.

The potency depends on the strength and the form that you use. For details on the potency of your product, ask your pharmacist.

Generic name: triamcinolone acetonide/emollient combination no.86
Pronunciation: (trye-am-SIN-oh-lone)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Dermasorb Ta

Intelligence content is not available yet.

Indications

The following indications are listed for Dermasorb Ta:

  • Allergic Dermatitis
  • Atopic Dermatitis
  • Contact Dermatitis
  • Discoid Lupus Erythematosus
  • Genital Organ Pruritus
  • Granuloma Annulare
  • Lichen Simplex Chronicus
  • Plaque Psoriasis
  • Pruritus Ani
  • Pruritus Of Skin
  • Pyoderma Gangrenosum
  • Scalp Psoriasis
  • Seborrheic Dermatitis
  • Skin Inflammation

Also known as: Atopic Eczema, Circumscribed Neurodermatitis, Dermatitis, Dermatitis Seborrheica, Dermatitis Venenata, Disseminated Neurodermatitis, Dyssebacea, Dyssebacia, Genital Pruritus, Itchy Skin Eruption, Lichen Annularis, Pruritic Dermatitis, Seborrhea Corporis, Seborrheic Eczema, Unna's Disease, Vidal's Disease.

Dosing

No dosing information is available for this tab.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data